Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.62), $0.17 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.